Seeking Alpha

Zogenix defends Zohydro

  • In response to congressional activity seeking a withdrawal of the recently-approved Zohydro (hydrocodone), Zogenix publishes its response to yesterday's hearing.
  • Zohydro's potency is equivalent to other commercially available pain pills but without acetaminophen.
  • In terms of maximum strength per pill, all other extended-release opioids have a higher dosage strength than Zohydro.
  • The company offers educational tools and safeguards to ensure the safe use of Zohydro in addition to the FDA-mandated REMS.
  • The company has established an External Safe Use Board of Experts to monitor the use of the product.
  • Sales representatives are not compensated on volume sales.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: